CYDY - CytoDyn reports preliminary leronlimab results from mid-stage breast cancer study

CytoDyn (CYDY) announces strong preliminary results from its Phase 1b/2 trials and compassionate use with a total of 30 metastatic triple-negative breast cancer (mTNBC) patients, treated with leronlimab in combination with carboplatin. Key findings from the interim 12-month analysis include:72% of patients had a decrease in CAMLs (cancer-associated macrophage-like cells) ~30 days after induction of leronlimabThe decrease in CAMLs was associated with:A ~300% increase in mean progression-free survival.A significant ~450% increase in overall survival.High CCR5 in tumor tissue biopsies may help to stratify patients likely to progress on leronlimab.Decreases in CAMLs and circulating tumor cells appear to be related to slower progression and lower mortality.CAMLs appear to identify populations that are responding to leronlimab.“We are very excited about these preliminary results and are eager to discuss the next regulatory steps based on this data," commented Scott Kelly, M.D., Chief Medical Officer and Chairman of the Board.

For further details see:

CytoDyn reports preliminary leronlimab results from mid-stage breast cancer study